<?xml version="1.0" encoding="UTF-8"?>
<p>No specific medicine or treatment is currently available for SARS-CoV-2-related diseases. Studies of remdesivir, phosphoramidate of an adenosine C-nucleoside analog, have brought attention to the possible application of this molecule as an anti-SARS-CoV-2 agent (
 <xref ref-type="fig" rid="biomolecules-10-01148-f007">Figure 7</xref>) [
 <xref rid="B57-biomolecules-10-01148" ref-type="bibr">57</xref>]. This RdRp inhibitor [
 <xref rid="B18-biomolecules-10-01148" ref-type="bibr">18</xref>] can inhibit the virus by inhibiting synthesis of viral nucleic acid, and has been recently authorized for emergency use in acute COVID-19 patients.
</p>
